Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

A Second Controversial Duchenne Approval For Company

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

FDAEntrance_1200x675
The approval went through the newly reorganized FDA Office of New Drugs

Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy therapy Vyondys 53 (golodirsen) has been approved by the US Food and Drug Administration in a surprise reversal of a rejection based on safety concerns.

The announcement came out of the blue on 12 December, as Sarepta had not disclosed that it had resubmitted its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip